Form 4: Vaxart CSO Sean Tucker's Tax-Related Stock Sale

Vaxart's SVP and Chief Scientific Officer, Sean Tucker, reported a disposition of 3,924 common shares for tax withholding purposes related to vested RSUs.

Summary

• Sean Tucker, SVP, Chief Scientific Officer of Vaxart, Inc. (VXRT), reported a transaction on March 28, 2026.
• The transaction involved the disposition of 3,924 shares of common stock at a price of $0.65 per share.
• These shares were withheld by Vaxart to cover income tax withholding and remittance obligations associated with the net settlement of Restricted Stock Units (RSUs) that vested on the same date.
• Following this transaction, Sean Tucker directly beneficially owns 882,811 shares of common stock.
• Additionally, Sean Tucker indirectly beneficially owns 51,465 shares through a joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares by spouse.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects the vesting of executive compensation (RSUs), indicating a planned compensation event rather than a discretionary sale.

Positives

• The transaction represents the vesting of Restricted Stock Units (RSUs), which is a form of executive compensation and indicates a planned compensation event.

Negatives

• A reduction of 3,924 shares in direct beneficial ownership, although this was for a non-discretionary tax withholding purpose.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Shares have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026.

Industry Context

StockSavvy.ai notes that tax-related dispositions of shares upon RSU vesting are a common occurrence for executives across various industries and do not typically signal a change in management's confidence in the company's prospects. This is a routine compliance filing reflecting standard equity compensation practices.

Comparison to Industry Standards

• This transaction is a standard tax withholding event upon the vesting of Restricted Stock Units (RSUs), a common practice for executive compensation across all industries. Companies like Pfizer, Moderna, and other biotech firms frequently report similar Form 4 filings for their executives when RSUs vest, as a portion of the shares are routinely withheld to cover statutory tax obligations. This is not indicative of a discretionary sale or a unique event for Vaxart.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine, non-discretionary tax-related transaction that does not reflect a change in the company's operational or strategic outlook.
• Employees: Reflects standard executive compensation practices, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares for tax withholding purposes related to RSU vesting. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Vaxart, VXRT, Sean Tucker, Form 4, insider transaction, stock sale, RSU, restricted stock units, tax withholding, beneficial ownership, Chief Scientific Officer